AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1569240 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac (30 mg or 90 mg)
Number of subjects: 145
Study 6488765 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 proprietary corticosteroid creams
Number of subjects: 20
Study 6488765 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 20
Study 30806596 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography prior to PAE (group B, n = 50)
Number of subjects: 100
Study 30806596 — intervention group
Group type: COMPARATOR
Intervention: No MR angiography prior to PAE (group A, n = 50)
Number of subjects: 100
Study 28179342 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 0
Study 25747747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral locking plate (LP group)
Number of subjects: 86
Study 25747747 — intervention group
Group type: COMPARATOR
Intervention: Dual buttress plates (DP group)
Number of subjects: 86
Study 23538267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0
Study 23538267 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 21917117 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 16
Study 21917117 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-electroacupuncture (placebo)
Number of subjects: 16
Study 19352055 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 64
Study 19352055 — intervention group
Group type: COMPARATOR
Intervention: Multi-daily insulin injections therapy (MDI)
Number of subjects: 64
Study 16144857 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation (HDcit)
Number of subjects: 8
Study 16144857 — intervention group
Group type: COMPARATOR
Intervention: Heparin (HDhep)
Number of subjects: 8
Study 16144857 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (HDdal)
Number of subjects: 8
Study 12936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imager (LDPI) for assessment of hyperaemia over the interphalangeal joints in patients with rheumatoid arthritis.
Number of subjects: 0
Study 12936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imager (LDPI) for assessment of blood flow during acupuncture.
Number of subjects: 0
Study 10632654 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg extended-release cisapride
Number of subjects: 19
Study 10632654 — intervention group
Group type: COMPARATOR
Intervention: 10 mg immediate-release cisapride
Number of subjects: 19
Study 8819499 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of codeine plus placebo
Number of subjects: 16
Study 8819499 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of codeine plus 100 mg of quinidine
Number of subjects: 16
Study 8819499 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of quinidine plus placebo
Number of subjects: 16
Study 1576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin 500 mg
Number of subjects: 0
Study 1576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin preparations
Number of subjects: 0
Study 1576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin esterase activity
Number of subjects: 0
Study 1576068 — intervention group
Group type: COMPARATOR
Intervention: Aspirin tablets
Number of subjects: 0
Study 1576068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2864935 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine pivalate (20 mg, oral administration once daily for 2-6 months)
Number of subjects: 60
Study 2864935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31706317 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen tube (DLT)
Number of subjects: 60
Study 31706317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB)
Number of subjects: 60
Study 30800921 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based learning module using PowerPoint
Number of subjects: 78
Study 26325116 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber (3.5 g/day)
Number of subjects: 65
Study 24901040 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (15 mg bupivacaine injected at L3-4)
Number of subjects: 12
Study 24901040 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study 22910171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir-zanamivir combination therapy
Number of subjects: 543
Study 22910171 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 543
Study 22910171 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir monotherapy
Number of subjects: 543
Study 22910171 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison between arms
Number of subjects: 543
Study 20082756 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenshi Qianghuo Dihuang Decoction (SQDD)
Number of subjects: 90
Study 20082756 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 90
Study 17284743 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled heme iron (2 mg as hemoglobin)
Number of subjects: 48
Study 17284743 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled heme iron (4 mg as hemoglobin)
Number of subjects: 48
Study 17284743 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled heme iron (8 mg as hemoglobin)
Number of subjects: 48
Study 17284743 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake (1 mg)
Number of subjects: 48
Study 17284743 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake (9 mg)
Number of subjects: 48
Study 16547384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin activity
Number of subjects: 179
Study 16547384 — intervention group
Group type: COMPARATOR
Intervention: Protein C level
Number of subjects: 179
Study 16547384 — intervention group
Group type: COMPARATOR
Intervention: TAT concentration
Number of subjects: 179
Study 16547384 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen concentration
Number of subjects: 179
Study 12064684 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 185
Study 12064684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 11833583 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 0
Study 11833583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7741186 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort; 200 micrograms twice daily)
Number of subjects: 61
Study 7741186 — intervention group
Group type: COMPARATOR
Intervention: Long-acting theophylline (Theodur; 200 mg twice daily)
Number of subjects: 61
Study 7741186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Budesonide + Theophylline)
Number of subjects: 61
Study 7741186 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Combination therapy
Number of subjects: 61
Study 7741186 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 61
Study 7741186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 61
Study 2044783 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL + PI of 5-FU
Number of subjects: 74
Study 2044783 — intervention group
Group type: COMPARATOR
Intervention: HAL alone
Number of subjects: 74
Study 2044783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 7234840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 32
Study 7234840 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 32
Study 7234840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Antacids (for isolated antral ulcer)
Number of subjects: 32
Study 7234840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (for primary gastric ulcer)
Number of subjects: 32
Study 7234840 — intervention group
Group type: COMPARATOR
Intervention: Antacids (for primary duodenal ulcer)
Number of subjects: 32
Study 7234840 — intervention group
Group type: COMPARATOR
Intervention: Secondary ulcer treatment
Number of subjects: 32
Study 31626833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning label on SSBs
Number of subjects: 401
Study 31626833 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie information label on all drinks
Number of subjects: 401
Study 31626833 — intervention group
Group type: COMPARATOR
Intervention: No additional label
Number of subjects: 401
Study 31626833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SEP participants
Number of subjects: 401
Study 31477140 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroid Option Grid PDAs
Number of subjects: 0
Study 31477140 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation phase
Number of subjects: 0
Study 31477140 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation phase
Number of subjects: 0
Study 26775811 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reporting to female experimenter
Number of subjects: 0
Study 26775811 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reporting to male experimenter
Number of subjects: 0
Study 26775811 — intervention group
Group type: EXPERIMENTAL
Intervention: Typed narratives
Number of subjects: 0
Study 26775811 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reporting
Number of subjects: 0
Study 25935584 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly progressive weight lifting
Number of subjects: 295
Study 25935584 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 295
Study 23393176 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin (iv bolus)
Number of subjects: 12
Study 23393176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iv bolus)
Number of subjects: 12
Study 21365183 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal estimates
Number of subjects: 0
Study 21365183 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor judgments
Number of subjects: 0
Study 19685114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine (group B)
Number of subjects: 40
Study 19685114 — intervention group
Group type: COMPARATOR
Intervention: 4 mg bupivacaine plus 25 microg fentanyl (group BF)
Number of subjects: 40
Study 17898396 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% oxygen
Number of subjects: 0
Study 17898396 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen (medical air)
Number of subjects: 0
Study 15258014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% jelly
Number of subjects: 59
Study 15258014 — intervention group
Group type: COMPARATOR
Intervention: Sub-Tenon's anaesthesia with lidocaine 2%
Number of subjects: 59
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalen sign
Number of subjects: 179
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinel sign
Number of subjects: 179
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist extension test
Number of subjects: 179
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure provocation test
Number of subjects: 179
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of signs
Number of subjects: 179
Study 11532560 — intervention group
Group type: EXPERIMENTAL
Intervention: All signs
Number of subjects: 179
Study 9364289 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid (C18:3 n‐6) at a dosage of 274 mg twice a day
Number of subjects: 60
Study 9364289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7966806 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐15 Valsalva
Number of subjects: 30
Study 7966806 — intervention group
Group type: COMPARATOR
Intervention: Standing cuff
Number of subjects: 30
Study 7966806 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 30
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g carbohydrate supplement
Number of subjects: 102
Study 3296962 — intervention group
Group type: COMPARATOR
Intervention: No carbohydrate supplement (control group)
Number of subjects: 102
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily insulin
Number of subjects: 102
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily insulin
Number of subjects: 102
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose measurement at 2200 h
Number of subjects: 102
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose measurement at 0800 h
Number of subjects: 102
Study 3296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin concentration in children on twice daily insulin with nocturnal hypoglycaemia
Number of subjects: 102
Study 31766076 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information about FSAs delivered via an emailed employee newsletter
Number of subjects: 11000
Study 31766076 — intervention group
Group type: EXPERIMENTAL
Intervention: Statements about the absolute returns offered by the accounts
Number of subjects: 11000
Study 31766076 — intervention group
Group type: EXPERIMENTAL
Intervention: Statements about the relative returns offered by the accounts
Number of subjects: 11000
Study 29846653 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154
Study 29846653 — intervention group
Group type: COMPARATOR
Intervention: EPA (2.7 g/d)
Number of subjects: 154
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital physician-assessed dyspnea
Number of subjects: 1567
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported early dyspnea relief
Number of subjects: 1567
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire score
Number of subjects: 1567
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 1567
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause hospitalization
Number of subjects: 1567
Study 27140204 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assessed and patient-reported dyspnea
Number of subjects: 1567
Study 25764960 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular matrix (ECM)
Number of subjects: 26
Study 25764960 — intervention group
Group type: COMPARATOR
Intervention: Human fibroblast-derived dermal substitute (HFDS)
Number of subjects: 26
Study 25764960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per DFU treatment for ECM
Number of subjects: 26
Study 25764960 — intervention group
Group type: COMPARATOR
Intervention: Cost per DFU treatment for HFDS
Number of subjects: 26
Study 25764960 — intervention group
Group type: COMPARATOR
Intervention: Total treatment costs comparison
Number of subjects: 26
Study 25764960 — intervention group
Group type: COMPARATOR
Intervention: Cost of care for two applications of HFDS
Number of subjects: 26
Study 24000921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led smoking cessation intervention
Number of subjects: 0
Study 24000921 — intervention group
Group type: EXPERIMENTAL
Intervention: New electronic medical record-based systems for identifying parents who smoke
Number of subjects: 0
Study 20634478 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional management of unbled brain arteriovenous malformations
Number of subjects: 124
Study 20634478 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural history)
Number of subjects: 124
Study 18258332 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo learning condition (n = 65)
Number of subjects: 130
Study 18258332 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple learning condition (n = 65)
Number of subjects: 130
Study 16842390 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 30
Study 16842390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 30
Study 16842390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reliable collision alarms
Number of subjects: 70
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% reliable collision alarms
Number of subjects: 70
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% reliable collision alarms
Number of subjects: 70
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (50% reliability)
Number of subjects: 70
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (75% reliability)
Number of subjects: 70
Study 14559409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (100% reliability)
Number of subjects: 70
Study 10937984 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 471
Study 10937984 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 471
Study 8906009 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (0.5 mg levonorgestrel and 0.1 mg ethinylestradiol)
Number of subjects: 32
Study 8906009 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg orally, repeated after 12 hours)
Number of subjects: 32
Study 8906009 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 32
Study 1925837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg, increased to 4, 10, and 20 mg)
Number of subjects: 35
Study 1925837 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg, increased to 10, 20, and 40 mg)
Number of subjects: 35
Study 1925837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6626435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 400 mg/day
Number of subjects: 6
Study 6626435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6626435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (2 or 20 micrograms/ml) in vitro
Number of subjects: 6
Study 6626435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole added to stored cells
Number of subjects: 6
Study 3936528 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 66
Study 3936528 — intervention group
Group type: COMPARATOR
Intervention: alfentanil
Number of subjects: 66
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP)
Number of subjects: 65
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CAP after treatment
Number of subjects: 65
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CAP >38 dB/m
Number of subjects: 65
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CAP <38 dB/m
Number of subjects: 65
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CAP
Number of subjects: 65
Study 30558054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen's kappa value
Number of subjects: 65
Study 27651323 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (600 mg/day)
Number of subjects: 24
Study 27651323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24156617 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) OCs
Number of subjects: 150
Study 24156617 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg EE and 150 μg LNG OCs
Number of subjects: 150
Study 22717828 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation
Number of subjects: 644
Study 22717828 — intervention group
Group type: COMPARATOR
Intervention: 28-mm femoral head articulation
Number of subjects: 644
Study 22717828 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation (primary arthroplasty)
Number of subjects: 644
Study 22717828 — intervention group
Group type: COMPARATOR
Intervention: 28-mm femoral head articulation (primary arthroplasty)
Number of subjects: 644
Study 22717828 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation (revision arthroplasty)
Number of subjects: 644
Study 22717828 — intervention group
Group type: COMPARATOR
Intervention: 28-mm femoral head articulation (revision arthroplasty)
Number of subjects: 644
Study 20149953 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 321
Study 18841784 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher tablets for 7 days
Number of subjects: 136
Study 18841784 — intervention group
Group type: COMPARATOR
Intervention: Qinlian capsule for 7 days
Number of subjects: 136
Study 15714120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin + EPT
Number of subjects: 19
Study 15714120 — intervention group
Group type: COMPARATOR
Intervention: Intralesional bleomycin alone
Number of subjects: 19
Study 12687806 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (Biv‐P) in wide QRS group (n=128)
Number of subjects: 158
Study 12687806 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (Biv‐P) in narrow QRS group (n=30)
Number of subjects: 158
Study 10503854 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume hydration (16-17 mL/kg)
Number of subjects: 77
Study 10503854 — intervention group
Group type: COMPARATOR
Intervention: Low volume hydration (1-2 mL/kg)
Number of subjects: 77
Study 8983875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 16
Study 8983875 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids infusion
Number of subjects: 16
Study 1901635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of angiotensin II (AII)
Number of subjects: 0
Study 1901635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 0
Study 1901635 — intervention group
Group type: EXPERIMENTAL
Intervention: AII infusion
Number of subjects: 0
Study 6292013 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/min) infusion for 5 minutes before and 20 minutes after intravenous glucose (0.5 g/kg body weight)
Number of subjects: 8